---
category: news
title: "Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care"
excerpt: "Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced results from a new utility study. The study confirmed the importance of risk assessment testing in addressing treatment ambiguity in the early stages of diabetic kidney disease (DKD) and improving patient engagement and adherence,"
publishedDateTime: 2021-06-03T11:13:00Z
originalUrl: "https://markets.businessinsider.com/news/stocks/utility-study-indicates-kidneyintelx-risk-assessment-can-address-treatment-ambiguity-in-primary-care-1030490658"
webUrl: "https://markets.businessinsider.com/news/stocks/utility-study-indicates-kidneyintelx-risk-assessment-can-address-treatment-ambiguity-in-primary-care-1030490658"
type: article
quality: 19
heat: 19
published: false

provider:
  name: Business Insider
  domain: businessinsider.com
  images:
    - url: "https://everyday-cc.github.io/ai/assets/images/organizations/businessinsider.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - AI in Healthcare
  - AI

secured: "IxzU8fOQ0EhXwdATamCZFQ2XqztV37X2RoJio0RQATPMB/lJ2EvUybWCQOrtS/xAgEqHTXu2xj8lQW0iSof8cF4Lk3htHv3M7miucNUFRVuRGFXG73vMuGH/QmvtpDexOkQ8Ofe+/5FddhftvlhQfjGx9CYdcUPebJRYH5z54bGLFccWUtDkBZRCr7/MiE2JkQOl/Q7MTQ+2PT6QRRHxHTeUd9JNBrVYPUa/VSH+QwQbxASeHVXaIxz5UCc1cBuBYGuqVIypDq7B70FGMY4RNcuRzN+0N0eFHHZtq1vSb9BrUirKkng9BCSDIzV2P09EMdeupetTj9Me5B/5cic7vZ4ljxNb1pEeSSMcS7hwK6g=;TwU6Axilo6NKR7zIJIIfWA=="
---

